VKTX
Income statement / Annual
Last year (2023), Viking Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Viking Therapeutics, Inc.'s net income was -$85.90 M.
See Viking Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$292,000.00 |
$291,000.00 |
$296,000.00 |
$277,000.00 |
$260,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$292,000.00 |
-$291,000.00 |
-$296,000.00 |
-$277,000.00 |
-$260,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$63.81 M
|
$54.23 M
|
$44.98 M
|
$31.93 M
|
$23.56 M
|
$19.04 M
|
$13.74 M
|
$9.00 M
|
$6.97 M
|
$22.22 M
|
| General & Administrative
Expenses |
$37.02 M
|
$16.12 M
|
$10.70 M
|
$10.73 M
|
$9.13 M
|
$7.12 M
|
$5.33 M
|
$4.85 M
|
$5.03 M
|
$1.24 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$37.02 M
|
$16.12 M
|
$10.70 M
|
$10.73 M
|
$9.13 M
|
$7.12 M
|
$5.33 M
|
$4.85 M
|
$5.03 M
|
$1.24 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.40 M |
$344,928.00 |
$1.06 M |
-$10.43 M |
$2.21 M |
| Operating Expenses |
$100.83 M |
$70.36 M |
$55.68 M |
$42.66 M |
$32.69 M |
$26.16 M |
$19.07 M |
$13.85 M |
$12.00 M |
$23.47 M |
| Cost And Expenses |
$100.83 M |
$70.36 M |
$55.68 M |
$42.66 M |
$32.69 M |
$26.16 M |
$19.07 M |
$13.85 M |
$12.00 M |
$23.47 M |
| Interest Income |
$15.02 M |
$1.59 M |
$703,000.00 |
$3.23 M |
$7.05 M |
$3.24 M |
$1,271.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$88,000.00 |
$0.00 |
$18,000.00 |
$106,000.00 |
$146,000.00 |
$404,000.00 |
$1.28 M |
$1.81 M |
$982,184.00 |
$628,676.00 |
| Depreciation &
Amortization |
$0.00
|
$291,000.00
|
$296,000.00
|
$277,000.00
|
$260,000.00
|
$26.16 M
|
$19.07 M
|
$13.85 M
|
-$10.43 M
|
$2.21 M
|
| EBITDA |
-$100.83 M
|
-$70.36 M
|
-$55.39 M
|
-$42.66 M
|
-$25.37 M
|
$4.66 M
|
$442,882.00
|
$1.15 M
|
-$22.39 M
|
-$21.26 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$14.93 M
|
$1.49 M
|
$692,000.00
|
$3.17 M
|
$6.91 M
|
$4.10 M
|
-$1.51 M
|
-$884,547.00
|
-$11.41 M
|
$1.58 M
|
| Income Before Tax |
-$85.90 M |
-$68.87 M |
-$54.99 M |
-$39.50 M |
-$25.78 M |
-$22.06 M |
-$20.58 M |
-$14.73 M |
-$23.40 M |
-$21.88 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$1.49 M |
-$988,000.00 |
-$3.44 M |
$6.99 M |
-$2.71 M |
$1.85 M |
$1.95 M |
$982,184.00 |
$628,676.00 |
| Net Income |
-$85.90 M |
-$67.38 M |
-$54.00 M |
-$36.05 M |
-$25.78 M |
-$22.06 M |
-$20.58 M |
-$14.73 M |
-$23.40 M |
-$21.88 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.91 |
-0.88 |
-0.7 |
-0.5 |
-0.36 |
-0.38 |
-0.79 |
-0.9 |
-3.68 |
-5.08 |
| EPS Diluted |
-0.91 |
-0.88 |
-0.7 |
-0.5 |
-0.36 |
-0.38 |
-0.79 |
-0.9 |
-3.68 |
-5.08 |
| Weighted Average Shares
Out |
$94.35 M
|
$76.83 M
|
$77.20 M
|
$72.60 M
|
$71.96 M
|
$57.58 M
|
$25.98 M
|
$16.28 M
|
$6.36 M
|
$4.31 M
|
| Weighted Average Shares
Out Diluted |
$94.35 M
|
$76.83 M
|
$77.20 M
|
$72.60 M
|
$71.96 M
|
$57.58 M
|
$25.98 M
|
$16.28 M
|
$6.36 M
|
$4.31 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
